Good morning :)
Place Order
Add to Watchlist

Samrat Pharmachem Ltd

SAMRATPH

Samrat Pharmachem Ltd

SAMRATPH
MaterialsCommodity Chemicals
SmallcapWith a market cap of ₹127 cr, stock is ranked 2,881
High RiskStock is 3.62x as volatile as Nifty
430.002.70% (+11.30)
430.002.70% (+11.30)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
MaterialsCommodity Chemicals
SmallcapWith a market cap of ₹127 cr, stock is ranked 2,881
High RiskStock is 3.62x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

MaterialsCommodity Chemicals
SmallcapWith a market cap of ₹127 cr, stock is ranked 2,881
High RiskStock is 3.62x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
19.761.960.24%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
31.173.551.31%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Samrat Pharmachem Limited is engaged in the production of pharmaceutical chemicals like Iodine salts and Bromine salts. The Company's finished products are used in various industries, including pharmaceuticals, chemicals, food, fertilizer and salt.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 20.45%, vs industry avg of 9.38%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.15% to 0.24%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 6.9%, vs industry avg of 4.33%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue63.4172.9093.19111.60138.03179.48222.38311.13282.96297.14
Raw Materialssubtract56.4662.9582.43103.53131.80162.02190.23288.00265.48287.94
Power & Fuel Costsubtract0.740.630.820.730.911.121.341.461.37
Employee Costsubtract0.660.760.850.941.001.050.961.071.11
Selling & Administrative Expensessubtract3.033.112.312.091.831.832.463.103.36
Operating & Other expensessubtract1.121.600.580.67-4.704.352.52-6.927.79
Depreciation/Amortizationsubtract0.440.430.410.420.430.490.590.640.650.65
Interest & Other Itemssubtract0.510.630.861.060.981.280.671.230.690.70
Taxes & Other Itemssubtract0.151.021.700.621.552.016.425.900.361.41
EPS0.975.7310.454.9813.6917.2555.6453.896.9620.84
DPS0.000.000.000.000.000.001.001.001.001.00
Payout ratio0.000.000.000.000.000.000.020.020.140.05

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
MaterialsCommodity Chemicals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Samrat Pharmachem Ltd59.181.960.24%
Solar Industries India Ltd116.8328.500.08%
Linde India Ltd132.3316.560.18%
Deepak Nitrite Ltd45.917.720.27%

Price Comparison

Compare SAMRATPH with any stock or ETF
Compare SAMRATPH with any stock or ETF
SAMRATPH
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding48.95%0.00%0.22%3.24%47.59%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep3.24%3.24%3.24%3.24%3.24%3.24%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 19, 2024

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 19, 2024

Cash Dividend

Ex DateEx DateSep 18, 2023

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 18, 2023

Cash Dividend

Ex DateEx DateSep 22, 2022

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 22, 2022

News & Opinions
Earnings
Samrat Pharmachem reports standalone net profit of Rs 2.66 crore in the September 2024 quarter

Net profit of Samrat Pharmachem reported to Rs 2.66 crore in the quarter ended September 2024 as against net loss of Rs 0.19 crore during the previous quarter ended September 2023. Sales declined 12.00% to Rs 70.17 crore in the quarter ended September 2024 as against Rs 79.74 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales70.1779.74 -12 OPM %4.800.28 - PBDT3.690.39 846 PBT3.520.23 1430 NP2.66-0.19 LP Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Samrat Pharmachem announces board meeting date

Samrat Pharmachem will hold a meeting of the Board of Directors of the Company on 14 November 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Samrat Pharmachem standalone net profit rises 239.34% in the June 2024 quarter

Net profit of Samrat Pharmachem rose 239.34% to Rs 2.07 crore in the quarter ended June 2024 as against Rs 0.61 crore during the previous quarter ended June 2023. Sales rose 40.61% to Rs 80.82 crore in the quarter ended June 2024 as against Rs 57.48 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales80.8257.48 41 OPM %3.191.34 - PBDT2.980.91 227 PBT2.820.75 276 NP2.070.61 239 Powered by Capital Market - Live

4 months agoCapital Market - Live